

Surrender of the Plaintiff's Claim in the Patent Litigation on Genetically Modified Mice

Osaka, Japan, February 22, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that plaintiff Collectis SA (France; hereafter "Collectis") has surrendered its claim against Shionogi for damages in a patent litigation relating to genetically modified mice. This is full and final resolution of this matter.

Collectis sued Shionogi for damages of approximately 970 million yen in the Osaka District Court on May 7, 2008 alleging that the technology on genetically modified mice Shionogi uses for research infringed patents owned by Institut Pasteur (Patent numbers: JP3059481 and JP3298842). Following a final hearing on August 26, 2011 in which the parties had been awaiting the Court's ruling, Collectis voluntarily dismissed its claim for damages on February 22, 2012. There are no further legal avenues available to Collectis in this matter and, accordingly, Shionogi cannot be found liable for the damages alleged by Collectis.

Shionogi values intellectual property and intends to continue to vigorously pursue its rights in these matters.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596